1. ALLA AKTIER
  2. NYHETER
  3. PROSTALUND

ProstaLund

Nyheter ProstaLund Nyheter alla bolag

New agreement - Esbjerg Hospital starts up with CoreTherm® treatments

ProstaLund has signed an agreement on CoreTherm® with the new customer Sydvestjysk Sygehus, with placement of the Coretherm® machine at Esbjerg Sygehus.

ProstaLund has signed an agreement with Sydvestjysk Sygehus in Denmark. The agreement means that ProstaLund installs the CoreTherm® machine with accessories at the clinic. The first CoreTherm® treatments are planned to be carried out in January 2024.

"It is pleasing news that another hospital will perform CoreTherm® treatments in Denmark and that patients will have more options" says Anders Kristensson, CEO ProstaLund AB.

For further information, please contact:

Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments

New agreement - Esbjerg Hospital starts up with CoreTherm® treatments

Datum 2023-12-12, kl 16:20
Källa MFN
Bifogade filer
New agreement - Esbjerg Hospital starts up with CoreTherm® treatments
Affiliate
Kopiera toppinvesterare! Med eToros innovativa CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för att använda CopyTrader-funktionen.
Copy Trading innebär inte investeringsråd. Värdet på dina investeringar kan gå upp eller ned. Ditt kapital löper risk.